Fortress Biotech, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Asset Purchase Agreements (Narrative) (Details)

Asset Purchase Agreements (Narrative) (Details)							1 Months Ended			12 Months Ended
Asset Purchase Agreements (Narrative) (Details)	Jul. 15, 2024 USD ($) director	Jun. 27, 2024 USD ($) item	May 13, 2024	Jul. 28, 2023 USD ($)	Apr. 21, 2023 USD ($)	Feb. 24, 2021 USD ($)	Dec. 31, 2024 USD ($)	Jul. 31, 2024 USD ($)	Dec. 31, 2023 USD ($) D	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Feb. 28, 2025 $ / shares	Jul. 31, 2022 USD ($)
Number of days to dispose of assets purchased			180 days
Purchase Price recorded in accrued expenses - other							$ 4,915,000		$ 817,000	$ 4,915,000	$ 817,000
Payments of milestones										700,000	500,000
Collaboration revenue										1,500,000	5,229,000
Tangible asset impairment charges											3,100,000
Asset purchase agreement to acquire Aevitas proprietary rights
Fair value of Aevitas interest retained					$ 2,600,000
Crystalys Therapeutics, Inc
Capitalization in equity securities	$ 150,000,000
Cyprium \| Sentynl APA
Payments of milestones							1,500,000
Cyprium \| Sentnyl
Contingent liability									4,500,000		4,500,000
Upfront fees payment						$ 8,000,000			$ 8,000,000
Collaboration revenue											700,000
Avenue \| InvaGen
Contingent fee payable from proceeds of future financing													$ 4,000,000
Percentage of contingent fee payable													7.50%
Aevitas
Loss from deconsolidation of Aevitas											$ (3,400,000)
Aevitas \| Maximum [Member] \| Asset purchase agreement to acquire Aevitas proprietary rights
Upfront payment to be paid					$ 140,000,000
Mustang
Purchase Price recorded in accrued expenses - other							1,300,000			1,300,000
Tangible asset impairment charges										2,600,000
Mustang \| UBriGene
Consideration Transferred		$ 1,400,000		$ 6,000,000
Consideration Transferred		$ 4,700,000
Gain on sale of asset				1,400,000
Transaction Related Expenses				$ 300,000
Interest rate on outstanding liability		5.00%
Upfront payment		$ 100,000						$ 100,000
Upfront payment due period \| item		5
Subsequent amount		$ 1,300,000
Subsequent payment due period		12 months
Purchase Price recorded in accrued expenses - other							1,300,000			1,300,000
Fair value of assets less cost to sell in repurchase transaction		$ 2,200,000
Remaining purchase consideration allocated to the supplies repurchased		2,500,000
Fair value of supplies with no alternative future use expensed as research and development expense		2,200,000
Fair Value of Supplies With Alternative Future Use Expensed as Research and Development Expense		300,000
Aggregate value of assets and associated supplies met the criteria to be classified as held for sale at the date of acquisition		2,200,000					$ 1,200,000			1,200,000
Outstanding receivable from uBriGene		6,900,000
Outstanding payables of the company		3,600,000
Net Receivable from uBriGene		3,300,000
Urica
Percentage of equity to be held	35.00%
Urica \| Crystalys Therapeutics, Inc
Urica's equity position	15.00%
Percentage of royalty on future net sales	3.00%
Reimbursement of Research and Development	$ 600,000
Number of directors \| director	1
Maximum repurchase amount of assets sold under agreements	$ 6,400,000
Amount of minimum qualified financing required	120,000,000
Liability	$ 600,000
Recorded accretion										$ 700,000
SPMA \| Cyprium \| Sentnyl
Number of days to assume control over development of CUTX-101 in the event that CUTX-101 NDA approval has not been obtained											45
SPMA \| Cyprium \| Sentnyl \| Manufacturing Services Agreement [Member]
Number of days to assume control over development of CUTX-101 in the event that CUTX-101 NDA approval has not been obtained \| D									45
Subsequent events \| Mustang
Stock offering, price per share \| $ / shares												$ 3.01
Net Assets Below 20 Million \| Mustang \| UBriGene
Asset acquisition consideration, threshold net assets considered for delay in subsequent payment		$ 20,000,000
Subsequent payment extended due period		6 months
FDA approval of the NDA \| Cyprium \| Sentnyl \| Maximum [Member]
Payments of milestones						$ 129,000,000
Annual net sales up to $75 million \| Cyprium \| Sentynl APA
Contingent liability									$ 75,000,000		$ 75,000,000
Royalty on net sales to be received (in percent)									3.00%
Annual net sales between $75 million and $100 million \| Cyprium \| Sentynl APA
Consideration Transferred									$ 100,000,000
Contingent liability									$ 75,000,000		$ 75,000,000
Royalty on net sales to be received (in percent)									8.75%
Annual net sales in excess of $100 million \| Cyprium \| Sentynl APA
Consideration Transferred									$ 100,000,000
Royalty on net sales to be received (in percent)									12.50%